Share on StockTwits

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) were the target of a large increase in short interest in May. As of May 15th, there was short interest totalling 14,246,393 shares, an increase of 37.5% from the April 30th total of 10,358,313 shares, Stock Ratings Network reports. Approximately 4.4% of the company’s shares are sold short. Based on an average daily trading volume, of 3,041,174 shares, the short-interest ratio is currently 4.7 days.

VRX has been the subject of a number of recent research reports. Analysts at Cantor Fitzgerald raised their price target on shares of Valeant Pharmaceuticals Intl to $209.00 in a research note on Monday, June 2nd. Separately, analysts at CIBC initiated coverage on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, May 21st. They set an “outperform” rating and a $160.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research note on Friday, May 16th. They now have a $153.00 price target on the stock. One research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals Intl currently has a consensus rating of “Buy” and an average price target of $150.90.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 127.46 on Monday. Valeant Pharmaceuticals Intl has a 52-week low of $81.94 and a 52-week high of $153.10. The stock’s 50-day moving average is $130.9 and its 200-day moving average is $128.3. The company’s market cap is $42.733 billion.

Valeant Pharmaceuticals Intl (NYSE:VRX) last announced its earnings results on Thursday, May 8th. The company reported $1.76 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.72 by $0.04. The company had revenue of $1.85 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company posted $1.30 earnings per share. The company’s quarterly revenue was up 76.6% on a year-over-year basis. On average, analysts predict that Valeant Pharmaceuticals Intl will post $8.75 earnings per share for the current fiscal year.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.